Trial Profile
A Phase II Study Evaluating the Safety and Efficacy of Eribulin in Combination with Gemcitabine in Patients with Advanced Triple Negative Breast Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Jun 2017
Price :
$35
*
At a glance
- Drugs Eribulin (Primary) ; Gemcitabine (Primary)
- Indications Advanced breast cancer; Triple negative breast cancer
- Focus Therapeutic Use
- 06 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
- 06 Jun 2017 New trial record